TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Quality Considerations for Manufacturing in Pharma

Quality Considerations for Manufacturing in Pharma

Quality Considerations for Continuous Manufacturing in the Pharmaceutical Industry

The FDA issued a draft guidance document  in February 2019 titled “Quality Considerations for Continuous Manufacturing, Guidance for Industry”. This guidance document contains information regarding the FDA’s current thinking on the quality considerations for continuous manufacturing of small-molecule and solid oral drug products. It is important to understand that this draft guidance document is currently in the ninety day consultation and review period. It has not yet been approved for implementation.

It outlines that the benefits associated with continuous manufacturing mean that the manufacturing process will ultimately result in an integrated manufacturing process with fewer steps and shorter processing times. If implemented correctly a continuous manufacturing process would provide the following benefits:

  • Smaller equipment footprint
  • Supporting an enhanced development approach (e.g., Quality by Design (QbD), use of Process Analytical Technology (PAT) and models)
  • Real-time product quality monitoring
  • Flexible operation to allow scale-up, scale-down, and scale-out to accommodate changing supply demands

The output of these improvements would ultimately reduce the number of drug product quality issues, lower manufacturing costs, and improve availability of quality medicines to patients.

Some key concepts of a continuous manufacturing process include the following:

Process Dynamics:

An understanding of process dynamics is essential for the identification and mitigation of risks to product quality. The different elements associated with process dynamics range from the input material attributes to process conditions to equipment design elements both during and after production. As a result of the dynamic nature of a continuous manufacturing process the risk assessment should consider process understanding of the integrated system in addition to each unit operation.

Control Strategy:

A Control Strategy is a key quality aspect to the successful implementation of continuous manufacturing. Establishing, maintaining, and refining a control strategy is a life cycle activity – from development to technology transfer to ongoing verification during the commercial manufacturing phase. An effective PQS strengthens the links across the stages of a product’s life cycle and enables the development and continuous improvement of the control strategy. Key elements of a control strategy include;

  • Control of input materials
  • Process Monitoring and Control
  • Material Diversion
  • Real Time release testing
  • Specification
  • Equipment
  • System Integration, Data Processing and Management

Process Validation:

The ability to evaluate real time data to maintain operations within established criteria to produce drug products with a high degree of assurance of meeting all the attributes they are intended to possess is an integral element of process validation. For the successful validation of a continuous manufacturing process, the FDA recommends that the following guidelines are incorporated:

  • Process Validation: General Principles and Practices
  • ICH Q8 Pharmaceutical Development
  • ICH Q9Quality Risk Management
  • ICH Q10Pharmaceutical Quality System
  • FDA’s three-phase model (1 Process Design; 2 Process Qualification; 3 Continued Process Verification)

Additional Pharmaceutical Quality System Considerations:

The guidance document also recommends that manufacturers should re-examine their quality management systems to ensure that is robust enough and covers the new challenges that continuous manufacturing presents such as handling process failures in real time, review of raw materials, change management and CAPA. An appropriate level of continuous manufacturing expertise in area such as quality, manufacturing operations and regulatory affairs should also be established, and training plans put in place where appropriate.

Scale Up:

Scale up is possible in three ways – increasing run time with no change to mass flow rate, increasing the mass flow rate or increasing both. Each method of scale up should be carefully examined to identify and assess risks. An advantage of continuous manufacturing is that the equipment used for process development can also be used for commercial manufacturing. Any scale up activities must be appropriately evaluated in the company’s change management process.

Stability:

As outlined in guidance for industry ICH Q1A(R2) Stability Testing of New Drug Substances and Products (https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products), data from stability studies should be provided on at least three primary batches of the drug product, and where possible, these should be manufactured by using different batches of the drug substance. Alternatively, stability samples could be obtained from a single continuous manufacturing campaign where manufacturing variability is captured (e.g., by introducing different batches of input material(s) in a sequential manner).

 

Bridging existing batch to continuous manufacturing:

As a change from batch to continuous manufacturing would result in a change in the scientific operating principle, the most appropriate filing strategy would be a Prior Approval Supplement (PAS). The FDA encourage any Manufacturers wishing to implement Continuous Manufacturing to discuss changes and bridging strategies to gain feedback prior to conducting any studies.

The continuous manufacturing draft guideline can be found on the FDA website: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM632033.pdf

If you would like more information on how PharmaLex can support you with the implementation of the different key concepts of a continuous manufacturing process please contact us on +353 1 846 4742 or contactirl@pharmalex.com.

Related posts
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Search
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
16 May

PharmaLex is proud to be a supporting sponsor at #AusMedtech2022 24 May-26 May. In keeping with our CSR, we are sponsoring reusable coffee cups at this event. Be sure to reuse your Coffee cup to support good sustainable practices and our environment.
https://www.ausmedtech.com.au/

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Our project team were very impressed with the quality of the research and the reports that you sent through. We didn’t need any convincing that your recommendations should be followed. It showed PharmaLex in a very positive light, and the Project Team are keen to work with you again.

    Leading European Specialist Pharma Company
    Head of Medical Writing and Publications
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for